Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Recurrent Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00230542
What this trial is testing

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute 44
Testing effectiveness (Phase 2)Study completedNCT00170573
What this trial is testing

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
North Eastern German Society of Gynaecological Oncology 77
Testing effectiveness (Phase 2)Looking for participantsNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Ended earlyNCT00849667
What this trial is testing

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Who this might be right for
Ovarian Cancer
Morphotek 1,100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Large-scale testing (Phase 3)UnknownNCT03705156
What this trial is testing

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Who this might be right for
Platinum-sensitive Relapsed Ovarian Cancer
Zai Lab (Shanghai) Co., Ltd. 265
Testing effectiveness (Phase 2)Looking for participantsNCT06040970
What this trial is testing

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Ovarian CancerMalignant Neoplasm of Uterus
Icahn School of Medicine at Mount Sinai 54
Testing effectiveness (Phase 2)Study completedNCT00023712
What this trial is testing

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
National Cancer Institute (NCI) 58
Testing effectiveness (Phase 2)Looking for participantsNCT05887609
What this trial is testing

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Who this might be right for
Ovary CancerPeritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 53
Testing effectiveness (Phase 2)Study completedNCT00325351
What this trial is testing

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Bayer 45
Large-scale testing (Phase 3)Study completedNCT03863860
What this trial is testing

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 252
Early research (Phase 1)Study completedNCT03732768
What this trial is testing

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

Who this might be right for
Peritoneal CarcinomatosisOvarian Cancer
Oncoinvent Solutions AS 21
Testing effectiveness (Phase 2)Looking for participantsNCT05551208
What this trial is testing

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Who this might be right for
Ovarian Cancer
Chongqing University Cancer Hospital 42
Large-scale testing (Phase 3)Not Yet RecruitingNCT07791732
What this trial is testing

Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)

Who this might be right for
Fallopian Tube CancerPrimary Peritoneal CancerHigh-Grade Serous Ovarian Cancer+1 more
Daiichi Sankyo 600
Testing effectiveness (Phase 2)Ended earlyNCT03891576
What this trial is testing

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Mario Negri Institute for Pharmacological Research 83
Large-scale testing (Phase 3)Study completedNCT01837251
What this trial is testing

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Who this might be right for
Recurrent Platinum-sensitive Ovarian Cancer
AGO Research GmbH 682
Testing effectiveness (Phase 2)Active Not RecruitingNCT04575961
What this trial is testing

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Who this might be right for
Ovarian CancerLow Grade Serous CarcinomaPrimary Peritoneal Carcinoma+1 more
North Eastern German Society of Gynaecological Oncology 33
Testing effectiveness (Phase 2)Study completedNCT00466986
What this trial is testing

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Southeastern Gynecologic Oncology 40
Large-scale testing (Phase 3)Study completedNCT03534453
What this trial is testing

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Relapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyPlatinum Sensitive
AstraZeneca 229
Early research (Phase 1)Study completedNCT00692900
What this trial is testing

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
University of Pittsburgh 25
Next Page
87